分子病態治療研究センター 遺伝子治療研究部

水上 浩明

ミズカミ ヒロアキ  (Hiroaki Mizukami)

基本情報

所属
自治医科大学 分子病態治療研究センター 遺伝子治療研究部 教授
学位
医学博士(自治医科大学(JMU))
M.D.

J-GLOBAL ID
200901034663759310
researchmap会員ID
1000273320

外部リンク

学歴

 1

論文

 237
  • Yuki Nakagami, Misako Komatsu, Ken Nakae, Masanari Otsuka, Junichi Hata, Hiroaki Mizukami, Hiroshi Takemori, Shin Ishii, Hideyuki Okano, Akiya Watakabe, Tetsuo Yamamori
    Neuroscience Research 226 105042-105042 2026年3月  査読有り
  • Yutaro Yamamoto, Takuto Katayama, Camila Fabbri, Sora Niwa, Daiki Okuhara, Mitsuhiro Iyori, Ammar A. Hasyim, Hiroaki Mizukami, Hisatoshi Shida, Stefanie Lopes, Shigeto Yoshida
    npj Vaccines 10(1) 2025年7月26日  
  • Ryota Watano, Kenji Ohba, Yoshihide Sehara, Yuka Hayashi, Yasushi Saga, Masashi Urabe, Tsukasa Ohmori, Hiroaki Mizukami
    Human gene therapy 36(11-12) 914-924 2025年6月  
    Gene therapy using adeno-associated virus (AAV) vectors is currently expanding to broad clinical applications. As the presence of a neutralizing antibody (NAb) against AAV capsids significantly restrains their efficacy, an accurate evaluation of NAb status is crucial for selecting appropriate candidates for gene therapy. Notably, cell-based NAb assays may not be sufficiently sensitive for detecting low-titer NAb, and few assays can evaluate multiple AAV serotypes using a commonly available cell. In this study, we developed a sensitive NAb assay against various AAV serotypes using commonly available HEK293 and Huh-7 cells. We found that adding glucose efficiently enhanced transgene expression across various AAV serotypes without causing cell damage. In addition, by combining a highly sensitive reporter gene, NanoLuc, the necessary dose of AAV vector was significantly reduced. The reduction of AAV dose resulted in the increased sensitivity of NAb detection as low as 100 vector genomes/cell. At the lower vector doses, sensitivity improvement was not observed regardless of serotypes, suggesting the limit of assay sensitivity of the cell-based NAb assay. These findings provide a highly sensitive methodology for assessing NAb titers and offer insights into conditions to attain maximal sensitivity in the cell-based NAb assay.
  • Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Eri Suizu, Suzuyo Takahashi, Akiyo Taneichi, Yuji Takei, Hiroaki Mizukami, Hiroyuki Fujiwara
    Cancer reports (Hoboken, N.J.) 8(4) e70202 2025年4月  
    BACKGROUND: Progesterone rapidly induces ovarian cancer cell death through non-genomic actions mediated by the membrane progesterone receptor (mPR). AIMS: We investigated the combined effects of progesterone and SN38, an active metabolite of irinotecan, on ovarian cancer cells. METHODS AND RESULTS: mPR-positive and PR-negative ovarian cancer cell lines were utilized in experiments. Tumor cells were exposed to SN38 or cisplatin for 48 h following exposure to progesterone for 30 min. The viable cell counts were measured using a colorimetric assay and the expression of topoisomerase I (TOPO-I), the direct target of SN38, was observed with or without exposure to progesterone. Moreover, we investigated the relationship between several types of programmed cell death and the SN38 sensitivity enhancement effect of progesterone using specific cell death inhibitors. The chemosensitivity to SN38 was 8.7- to 26.0-fold higher with the administration of progesterone than that without (p < 0.01), but not to cisplatin in ovarian cancer cells. Progesterone suppressed the expression of TOPO-I mRNA by less than 50% (p < 0.01). Furthermore, among various programmed cell death inhibitors, only the ferroptosis inhibitor attenuated the progesterone-induced SN38 chemosensitivity enhancement effect. CONCLUSIONS: Progesterone increased sensitivity to SN38 by suppressing TOPO-I expression and inducing ferroptosis. The combination of progesterone and irinotecan could be a novel treatment modality for ovarian cancer.
  • Yasuyuki Osanai, Batpurev Battulga, Reiji Yamazaki, Kenta Kobayashi, Kenji Kobayashi, Yuka Nakamura, Masaki Ueno, Hiroaki Mizukami, Yumiko Yoshimura, Nobuhiko Ohno
    2025年3月6日  
    Myelination in the visual pathway is critical for transmitting visual information from retina to the brain. Reducing visual experience shortens myelin sheath length and slows the conduction velocity of the optic nerve. However, the mechanism underlying such experience-dependent myelination is unclear. Here, we found that closing both eyes, binocular deprivation (BD), during the juvenile period less affects the optic nerve myelination than monocular deprivation (MD) via GABA signaling. RNA-seq analysis of optic nerves from MD and BD mice revealed that GABAergic signaling is downregulated on the deprived side of MD compared to the intact side and BD. Inhibition of GABAergic signaling during the juvenile period resulted in myelin sheath shortening and excessive oligodendrocyte generation in normal mice, similar to the changes observed in MD mice. Enhancing GABAergic signaling rescued the myelin sheath shortening and excessive oligodendrocyte generation in the optic nerve of MD mice. Furthermore, we identified novel GABAergic neurons located within the optic nerve, whose neurites form belt-like presynaptic structures with the oligodendrocyte lineage cells, suggesting a potential source of the GABAergic inputs into oligodendrocytes. Our results indicate that the myelination of visual pathway is maintained by binocular visual inputs via intra-nerve GABA signaling.

MISC

 190

書籍等出版物

 1

共同研究・競争的資金等の研究課題

 33

産業財産権

 2